Tags

Type your tag names separated by a space and hit enter

Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Calcif Tissue Int. 2007 Aug; 81(2):73-80.CT

Abstract

Risedronate is used in osteoporosis treatment. Postmenopausal women enrolled in the Vertebral Efficacy with Risedronate Therapy trial received either risedronate (5 mg/day) or placebo for 3 years. Subjects received calcium and vitamin D supplementation if deficient at baseline. Lumbar spine bone mineral density (BMD) was measured at baseline and at 3 years. Quantitative back-scattered electron imaging (qBEI) was performed on paired iliac crest biopsies (risedronate, n = 18; placebo, n = 13) before and after treatment, and the mineral volume fraction in the trabecular bone was calculated. Combining dual-energy X-ray absorptiometric values with the mineral volume fraction for the same patients allowed us to calculate the relative change in trabecular bone volume with treatment. This showed that the effect on BMD was likely to be due partly to changes in matrix mineralization and partly due to changes in bone volume. After treatment, trabecular bone volume in the lumbar spine tended to increase in the risedronate group (+2.4%, nonsignificant) but there was a significant decrease (-3.7%, P < 0.05) in the placebo group. Calcium supplementation with adequate levels of vitamin D led to an approximately 3.3% increase in mineral content in the bone material independently of risedronate treatment. This increase was larger in patients with lower matrix mineralization at baseline and likely resulted from correction of calcium/vitamin D deficiency as well as from reduced bone remodeling. Combining BMD and bone mineralization density distribution data show that in postmenopausal osteoporosis 3-year treatment with risedronate preserves or may increase trabecular bone volume, unlike placebo. This analysis also allows, for the first time, separation of the contributions of bone volume and matrix mineralization to the increase in BMD.

Authors+Show Affiliations

Department of Biomaterials, Max Planck Institute of Colloids and Interfaces, Research Campus Golm, D-14424, Potsdam, Germany. fratzl@mpikg.mpg.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17612779

Citation

Fratzl, Peter, et al. "Evidence That Treatment With Risedronate in Women With Postmenopausal Osteoporosis Affects Bone Mineralization and Bone Volume." Calcified Tissue International, vol. 81, no. 2, 2007, pp. 73-80.
Fratzl P, Roschger P, Fratzl-Zelman N, et al. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. Calcif Tissue Int. 2007;81(2):73-80.
Fratzl, P., Roschger, P., Fratzl-Zelman, N., Paschalis, E. P., Phipps, R., & Klaushofer, K. (2007). Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. Calcified Tissue International, 81(2), 73-80.
Fratzl P, et al. Evidence That Treatment With Risedronate in Women With Postmenopausal Osteoporosis Affects Bone Mineralization and Bone Volume. Calcif Tissue Int. 2007;81(2):73-80. PubMed PMID: 17612779.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. AU - Fratzl,Peter, AU - Roschger,Paul, AU - Fratzl-Zelman,Nadja, AU - Paschalis,Eleftherios P, AU - Phipps,Roger, AU - Klaushofer,Klaus, PY - 2007/7/7/pubmed PY - 2007/11/2/medline PY - 2007/7/7/entrez SP - 73 EP - 80 JF - Calcified tissue international JO - Calcif Tissue Int VL - 81 IS - 2 N2 - Risedronate is used in osteoporosis treatment. Postmenopausal women enrolled in the Vertebral Efficacy with Risedronate Therapy trial received either risedronate (5 mg/day) or placebo for 3 years. Subjects received calcium and vitamin D supplementation if deficient at baseline. Lumbar spine bone mineral density (BMD) was measured at baseline and at 3 years. Quantitative back-scattered electron imaging (qBEI) was performed on paired iliac crest biopsies (risedronate, n = 18; placebo, n = 13) before and after treatment, and the mineral volume fraction in the trabecular bone was calculated. Combining dual-energy X-ray absorptiometric values with the mineral volume fraction for the same patients allowed us to calculate the relative change in trabecular bone volume with treatment. This showed that the effect on BMD was likely to be due partly to changes in matrix mineralization and partly due to changes in bone volume. After treatment, trabecular bone volume in the lumbar spine tended to increase in the risedronate group (+2.4%, nonsignificant) but there was a significant decrease (-3.7%, P < 0.05) in the placebo group. Calcium supplementation with adequate levels of vitamin D led to an approximately 3.3% increase in mineral content in the bone material independently of risedronate treatment. This increase was larger in patients with lower matrix mineralization at baseline and likely resulted from correction of calcium/vitamin D deficiency as well as from reduced bone remodeling. Combining BMD and bone mineralization density distribution data show that in postmenopausal osteoporosis 3-year treatment with risedronate preserves or may increase trabecular bone volume, unlike placebo. This analysis also allows, for the first time, separation of the contributions of bone volume and matrix mineralization to the increase in BMD. SN - 0171-967X UR - https://www.unboundmedicine.com/medline/citation/17612779/Evidence_that_treatment_with_risedronate_in_women_with_postmenopausal_osteoporosis_affects_bone_mineralization_and_bone_volume_ L2 - https://dx.doi.org/10.1007/s00223-007-9039-8 DB - PRIME DP - Unbound Medicine ER -